Arlington, VA, and Reykjavik, Iceland—October 19, 2020—Kerecis Limited, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, has created Viruxal Limited, a separate subsidiary to continue the research, development and commercialization of its Viruxal tissue-protection technology.
“Our patented, fatty-acid-rich fish-skin and wound-spray technologies have proven effective in treating wounds and reducing the risk of infection,” explained G. Fertram Sigurjonsson, founder and CEO of Kerecis. “We’ve now spun off the infection-control portion of our technology into a separate subsidiary.”
Viruxal Limited will focus on over-the-counter applications of the technology in the fight of viral respiratory diseases such as COVID-19. “Kerecis will remain focused on its wound-care and soft-tissue-reconstruction products,” added Sigurjonsson.
For information about Viruxal visit www.viruxal.com.